MNOV Company Profile and Key Details

Q: Who are the executives of MNOV?

Mr. John O'Neil CPAControllerMr. Jason J. Kruger CPAChief Financial Officer & Principal Financial OfficerDr. Yuichi Iwaki M.D., Ph.D.Co-Founder, Pres, Chief Executive Officer & Executive DirectorDr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.Chief Medical Officer & DirectorDr. David H. Crean M.B.A., Ph.D.Chief Bus. Officer

NASDAQ : MNOV

MediciNova

$1.41

-0.025-1.75%

Open: 2:56 PM

70.05

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

MediciNova, Inc. (MNOV) stock declined over -1.75%, trading at $1.41 on NASDAQ, down from the previous close of $1.43. The stock opened at $1.43, fluctuating between $1.39 and $1.44 in the recent session.

Stock Snapshot

1.43

Prev. Close

68.9M

Market Cap

1.39

Day Low

-5.62

P/E Ratio

-0.25

EPS (TTM)

-0.15

Cash Flow per Share

1.43

Open

49.04M

Number of Shares

1.435

Day High

85.8%

Free Float in %

1.27

Book Value

48.42K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	1.44	1.45	1.41	1.43	103.07K
Dec 17, 2025	1.48	1.51	1.47	1.47	63.44K
Dec 16, 2025	1.52	1.52	1.48	1.48	48.07K
Dec 15, 2025	1.55	1.55	1.52	1.52	31.36K
Dec 12, 2025	1.49	1.55	1.48	1.54	68.73K
Dec 11, 2025	1.53	1.54	1.51	1.51	43.01K
Dec 10, 2025	1.53	1.56	1.51	1.51	111.69K
Dec 09, 2025	1.51	1.57	1.51	1.54	72.65K
Dec 08, 2025	1.58	1.58	1.50	1.51	66.41K
Dec 05, 2025	1.56	1.60	1.55	1.56	98.82K
Dec 04, 2025	1.53	1.55	1.48	1.55	103.66K
Dec 03, 2025	1.49	1.51	1.47	1.51	76.67K
Dec 02, 2025	1.43	1.48	1.43	1.47	65.49K
Dec 01, 2025	1.45	1.46	1.41	1.41	52.52K
Nov 28, 2025	1.46	1.47	1.45	1.45	52.42K
Nov 26, 2025	1.53	1.53	1.45	1.45	119K
Nov 25, 2025	1.42	1.53	1.42	1.52	107.18K
Nov 24, 2025	1.43	1.52	1.42	1.42	440.09K
Nov 21, 2025	1.43	1.45	1.40	1.43	57.05K
Nov 20, 2025	1.43	1.45	1.41	1.42	39.11K

Contact Details

La Jolla, CA 92037

United States

https://www.medicinova.com 858 373 1500

About Company

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Stock Peers

ARGX

7.94+0.94%

argenx SE$854.99 REGN

19.25+2.57%

Regeneron Pharmaceuticals, Inc.$767.96 MDGL

46.61+8.56%

Madrigal Pharmaceuticals, Inc.$591.02 UTHR

10.13+2.00%

United Therapeutics Corporation$517.13 VRTX

8.82+1.97%

Vertex Pharmaceuticals Incorporated$456.20 ALNY

4.19+1.06%

Alnylam Pharmaceuticals, Inc.$400.23 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

3.66001+1.36%

Praxis Precision Medicines, Inc.$272.92 KRYS

7.43+3.18%

Krystal Biotech, Inc.$240.80 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

MediciNova, Inc. (NASDAQ:MNOV) closed at $1.41 USD, losing -$0.02 (-1.75%) from the previous close of $1.43. The stock is currently mid-range between its 52-week high and low $1.13 and $2.20. With a market capitalization of about $68.90 million, MediciNova, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 976.45 thousand shares, volume is running light vs its 52-week average. Headquartered in La Jolla, CA, MediciNova, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yuichi Iwaki, the company employs approximately 13 people and listed since December 08, 2006. MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -3.8%, SMA50 1.61%, SMA200 4.31%). The stock’s 14-day RSI is 45.8 (neutral), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.06% below its high and over 26.55% above its low. Average 10-day trading volume of 62.93 thousand shares is below the 3-month average of 872.29 thousand, indicating normal recent market interest.

Valuation Metrics

MediciNova, Inc. trades at a P/E ratio of -5.94, slightly below the S&P 500 average, with a price-to-sales ratio of 521.01 and a price-to-book ratio of 1.5 suggesting the stock is closer to book value. The P/FCF stands at -0.01, also above market averages.

Dividend & Fair Value

MediciNova, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.82. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

MediciNova, Inc. generated EPS of -$0.24 over the past year. Five-year average earnings growth is 5.56%. Wall Street analysts project EPS growth of -20.26% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.12. Next year's EPS is expected at -$52.38. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $5.00. The high target offers 529.37% upside. The low target suggests 249.65% downside. The mean target is $8.64. This offers 504.2% upside. MediciNova, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -25.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -10.68% in August 14, 2024.

Shareholding & Insider Activity

MediciNova, Inc. has 49.05 million shares outstanding. The public float is 42.08 million shares, elevated short interest at 0.29% of float. This equals 120.90 thousand shares. The short ratio is 2.73 days. Institutional investors hold 22.49% of the float. Insiders own 2.98%. IWAKI YUICHI holds 780.68 thousand shares, Izumi Tatsuo has 600.00 thousand shares and Matsuda Kazuko has 111.48 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, MediciNova generated $1.00M in revenue, or $0.02 per share. Gross margin was 97.97%, operating margin -990.03%, and net profit margin -857.15%. Returns are negative, with ROA at -12.93% and ROE at -13.74%.
On valuation metrics, MediciNova trades at a P/E of -5.94, P/S of 521.01 and P/B of 1.50. The current ratio is 13.26 and quick ratio is 13.26. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1211.00 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -20186.93.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, MediciNova posted revenue of $1.00M, down slightly from $0.00 in the prior quarter. Gross profit was $979.71K (margin 97.97%). Operating income was - $9.90M (margin -990.0%). Net income was- $8.57M (EPS - $0.17).
The company ended the quarter with $51.00M in cash and short-term investments, a total debt of $215.93K, and net debt of - $50.78M. Total assets were $66.27M, with equity of $62.38M. Financials further reflected weakness, with operating cash flow of - $7.43M, free cash flow of - $7.45M, and capital expenditures of - $21.30K.

Price Forecast & Outlook

Our AI price prediction model suggests that MediciNova, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.4%, with price expected at $1.45 by January 02, 2026, within a range of $1.37 to $1.54 3-Month Outlook: Projected fall of -23.08%, reaching $1.10 by March 19, 2026, with a range of $1.00 to $1.19. 1-Year Outlook: Projected gain of 481.82%, with price at $8.32 by December 18, 2026, within a range of $1.42 to $10.92.

Key Takeaways

MediciNova, Inc. (NASDAQ:MNOV) shares are down -31.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MediciNova, Inc. trading at a premium to the broader market with a P/E of -5.94. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.35, suggesting 623.78% upside. Our AI forecast model points to short-term strength (1.4% over two weeks), a medium-term fall (-23.08% over three months), and a longer-term gain (481.82% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current MediciNova, Inc. (MNOV) stock price?

MediciNova, Inc. (NASDAQ: MNOV) stock price is $1.41 in the last trading session. During the trading session, MNOV stock reached the peak price of $1.44 while $1.39 was the lowest point it dropped to. The percentage change in MNOV stock occurred in the recent session was -1.75% while the dollar amount for the price change in MNOV stock was - $0.03.

MNOV's industry and sector of operation?

The NASDAQ listed MNOV is part of Biotechnology industry that operates in the broader Healthcare sector. MediciNova, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MNOV?

Mr. John O'Neil CPA
Controller
Mr. Jason J. Kruger CPA
Chief Financial Officer & Principal Financial Officer
Dr. Yuichi Iwaki M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Executive Director
Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.
Chief Medical Officer & Director
Dr. David H. Crean M.B.A., Ph.D.
Chief Bus. Officer

How MNOV did perform over past 52-week?

MNOV's closing price is 26.55% higher than its 52-week low of $1.13 where as its distance from 52-week high of $2.20 is -35.59%.

How many employees does MNOV have?

Number of MNOV employees currently stands at 13.

Link for MNOV official website?

Official Website of MNOV is: https://www.medicinova.com

How do I contact MNOV?

MNOV could be contacted at phone 858 373 1500 and can also be accessed through its website. MNOV operates from 4275 Executive Square, La Jolla, CA 92037, United States.

How many shares of MNOV are traded daily?

MNOV stock volume for the day was 48.42K shares. The average number of MNOV shares traded daily for last 3 months was 976.45K.

What is the market cap of MNOV currently?

The market value of MNOV currently stands at $68.90M with its latest stock price at $1.41 and 49.04M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	13
Beta	0.48
Sales or Revenue	$1.00M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MNOV Company Profile and Key Details

MediciNova

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Valuation Metrics